Home » Clinical Trials » Therapeutic Areas
Therapeutic Areas: Neurology
Disease Category: Parkinson's Disease
Trial Information
Phase II - Determining Mirapex ER efficacy, safety and tolerability in the treatment Parkinson's Disease
To determine the efficacy, safety and tolerability of Mirapex ER
compared with placebo and Mirapex IR in patients with early onset
of idiopathic Parkinson's Disease.
Patient Inclusion Criteria:
- Idiopathic Parkinson's Disease diagnosed within five
years
- 30 years and older
- Anti-Parkinson treatment with anti-cholinergics, MAO
inhibitors, and beta blockers allowed if there has been a stable
dose for at least four weeks
- Modified Hoehn and Yahr stages 1-3
Patient Exclusion Criteria:
- Atypical Parkinsonian syndromes
- History of major psychological, neurological or
neurodegenerative conditions
- History or recent diagnosis of malignant melanoma
- Treated with L-Dopa for more than eight weeks prior to starting
in study
- Treated with a dopamine agonist within four weeks prior to
starting in study
Sanja Obradov, Research Coordinator
Banner Sun Health Research Institute
10515 W. Santa Fe Drive
Sun City, AZ 85351
Phone: 623-876-5468
View Google Map
DISCLAIMER: This site is run by CenterWatch, a publishing company that focuses on the
clinical trials industry. The information provided in this service is designed
to help patients find clinical trials that may be of interest to them, and to
help patients contact the centers conducting the research. CenterWatch is
neither promoting this research nor involved in conducting any of these
trials.
